Delving into the Latest Updates on HRS-2543 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

ERK

Mechanism

ERK inhibitors(ERK subfamily inhibitors)

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Advanced cancer

Originator Organization-

Active Organization-

Inactive Organization

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

Observe the dose-limiting toxicity of HRS2543 in subjects with advanced malignant tumors, determine the maximum tolerated dose of HRS2543 and the recommended dose for Phase II clinical studies. Evaluate the safety, efficacy, pharmacokinetics and pharmacodynamic characteristics of HRS2543 in subjects with advanced malignant tumors;

Start Date17 Dec 2021

Sponsor / Collaborator

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

[+1]

100 Clinical Results associated with HRS-2543

Login to view more data

100 Translational Medicine associated with HRS-2543

Login to view more data

100 Patents (Medical) associated with HRS-2543

Login to view more data

100 Deals associated with HRS-2543

Login to view more data